Cargando…

Aquaporin-4 antibody titration in NMO patients treated with rituximab: A retrospective study

OBJECTIVE: We undertook an observational retrospective study to investigate the usefulness of aquaporin-4 (AQP4) antibodies (Ab) titration in the management of patients with neuromyelitis optica (NMO) treated with rituximab (RTX) by studying (1) the correlation between AQP4-Ab titer and disease acti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Valentino, Paola, Marnetto, Fabiana, Granieri, Letizia, Capobianco, Marco, Bertolotto, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5182057/ https://www.ncbi.nlm.nih.gov/pubmed/28054001 http://dx.doi.org/10.1212/NXI.0000000000000317

Ejemplares similares

Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders
por: Marcinnò, Andrea, et al.
Publicado: (2018)

Evaluation of a Multiparametric Immunofluorescence Assay for Standardization of Neuromyelitis Optica Serology
por: Granieri, Letizia, et al.
Publicado: (2012)

The impact of pre-freezing storage time and temperature on gene expression of blood collected in EDTA tubes
por: Martire, Serena, et al.
Publicado: (2022)

The Selective Agonist for Sphingosine-1-Phosphate Receptors Siponimod Increases the Expression Level of NR4A Genes in Microglia Cell Line
por: Montarolo, Francesca, et al.
Publicado: (2022)

Aquaporin-4 antibody isoform binding specificities do not explain clinical variations in NMO
por: Kitley, Joanna, et al.
Publicado: (2015)

Aquaporin 4-specific T cells and NMO-IgG cause primary retinal damage in experimental NMO/SD
por: Zeka, Bleranda, et al.
Publicado: (2016)

Identification of geraldol as an inhibitor of aquaporin-4 binding by NMO-IgG
por: Wang, Jie, et al.
Publicado: (2020)

Circulating microRNAs as biomarkers for rituximab therapy, in neuromyelitis optica (NMO)
por: Vaknin-Dembinsky, Adi, et al.
Publicado: (2016)

Comparative Analysis for the Presence of IgG Anti-Aquaporin-1 in Patients with NMO-Spectrum Disorders
por: Sánchez Gomar, Ismael, et al.
Publicado: (2016)

Peculiar Cytological Cerebrospinal Fluid Pattern in a Case of Encephalomyelitis During Anti-Tumor Necrosis Factor-α Therapy
por: Motuzova, Yana, et al.
Publicado: (2015)

Finding NMO
por: Daneman, Richard
Publicado: (2016)

Where Do AQP4 Antibodies Fit in the Pathogenesis of NMO?
por: Kinoshita, Makoto, et al.
Publicado: (2012)

Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody–Associated Disease: CHANCE(NMO) Study
por: Hümmert, Martin W., et al.
Publicado: (2022)

Learning from Nature: Pregnancy Changes the Expression of Inflammation-Related Genes in Patients with Multiple Sclerosis
por: Gilli, Francesca, et al.
Publicado: (2010)

Immune and Epstein-Barr virus gene expression in cerebrospinal fluid and peripheral blood mononuclear cells from patients with relapsing-remitting multiple sclerosis
por: Veroni, Caterina, et al.
Publicado: (2015)

Highly encephalitogenic aquaporin 4-specific T cells and NMO-IgG jointly orchestrate lesion location and tissue damage in the CNS
por: Zeka, Bleranda, et al.
Publicado: (2015)

Benign COVID-19 in an aggressive case of aquaporin-4 Neuromyelitis optica treated with tocilizumab
por: Vecchio, Domizia, et al.
Publicado: (2021)

Natalizumab treatment reduces L-selectin (CD62L) in CD4(+) T cells
por: Spadaro, Michela, et al.
Publicado: (2015)

Therapy of NMO spectrum disorders
por: Biswas, Atanu, et al.
Publicado: (2015)

Classifying the antibody-negative NMO syndromes: Clinical, imaging, and metabolomic modeling
por: Yeo, Tianrong, et al.
Publicado: (2019)

Rheumatoid arthritis with aquaporin-4 antibody-positive neuromyelitis optica receiving rituximab therapy
por: Reen Wang, Chrong, et al.
Publicado: (2021)

Tailoring Rituximab According to CD27-Positive B-Cell versus CD19-Positive B-Cell Monitoring in Neuromyelitis Optica Spectrum Disorder and MOG-Associated Disease: Results from a Single-Center Study
por: Bruschi, Nicolò, et al.
Publicado: (2023)

Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO
por: Gelfand, Jeffrey M., et al.
Publicado: (2014)

Neurodegeneration in MS and NMO: The Eye and the Blood
por: Petzold, Axel, et al.
Publicado: (2011)

Neuromyelitis optica (NMO) and autoimmune thyroiditis
por: Sudulagunta, Sreenivasa Rao, et al.
Publicado: (2015)

Vitamin D Binding Protein Isoforms and Apolipoprotein E in Cerebrospinal Fluid as Prognostic Biomarkers of Multiple Sclerosis
por: Perga, Simona, et al.
Publicado: (2015)

Autoimmune thyroiditis associated with neuromyelitis optica (NMO)
por: Sudulagunta, Sreenivasa Rao, et al.
Publicado: (2015)

Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica
por: Waters, Patrick, et al.
Publicado: (2016)

Autoimmune Myelitis and Myocarditis in a Patient With Anti-Aquaporin-4, Antinuclear, and Antiphospholipid Autoantibodies: The Neuromyelitis Optica-Systemic Lupus Erythematosus (NMO-SLE) Overlap Syndrome
por: Mader, Edward C, et al.
Publicado: (2022)

Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis
por: Borisow, Nadja, et al.
Publicado: (2018)

Lack of KIR4.1 autoantibodies in Japanese patients with MS and NMO
por: Higuchi, Osamu, et al.
Publicado: (2016)

Mild COVID-19 infection in an NMO patient treated with tocilizumab: a confirmation of anti-IL-6 protective role?
por: Mantero, Vittorio, et al.
Publicado: (2020)

Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS
por: Gahlen, Anna, et al.
Publicado: (2017)

Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab
por: Boyer-Suavet, Sonia, et al.
Publicado: (2020)

NMO-IgG: A Specific Biomarker for Neuromyelitis Optica
por: Weinshenker, Brian G., et al.
Publicado: (2006)

Wallenda-Nmo Axis Regulates Growth via Hippo Signaling
por: Wang, Xianping, et al.
Publicado: (2021)

Wernicke’s Encephalopathy Precipitated by Area Postrema Syndrome of NMO-SD
por: Anuradha, Mahto, et al.
Publicado: (2023)

Development of anti-rituximab antibodies in rituximab-treated patients: Related parameters & consequences
por: Saffari, Fatemeh, et al.
Publicado: (2022)

Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment
por: Masuccio, Fabio Giuseppe, et al.
Publicado: (2020)

Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies?
por: Maillart, Elisabeth, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ph8j4bbf3ffqf9f56su5fu71qf